---
company: MetaVia Inc.
ticker: MTVA
form: 8-K
filed: 2026-08-06
accession: 0001104659-26-091981
source: https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/
---

# MetaVia (MTVA) earnings release, August 6, 2026

MetaVia Inc. (MTVA) · Form 8-K, Item 2.02 · Filed 2026-08-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/)

​

​

​

​

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

​

All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726

​

16-Week Topline Data Expected in the Fourth Quarter of 2026

​

CAMBRIDGE, Mass., August 6, 2026 – MetaVia Inc.

(Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate strategic update.

​

“During the second quarter of 2026, and subsequently, we continued to execute across both of our clinical development programs while further strengthening the differentiated profile of DA-1726 as a dual GLP-1/glucagon receptor agonist,” stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. “Most recently, all active patients in both cohorts of our ongoing Phase 1 Part 3 study successfully reached the highest planned dose levels of 48 mg and 64 mg, representing an important execution milestone as we prepare for our 16-week topline data readout, expected in the fourth quarter of 2026. Also of note, during the quarter, we presented additional data from our 48 mg Phase 1 study of DA-1726 at both the EASL and ADA scientific conferences, which demonstrated up to 9.1% mean weight loss after just eight weeks of treatment, meaningful reductions in waist circumference and encouraging liver-related findings, reinforcing our confidence in DA-1726's potential best-in-class profile and its potential to address multiple aspects of cardiometabolic disease. Based on the continued trajectory of weight loss through eight weeks without evidence of plateau on the 48 mg dosage, we believe the ongoing 16-week study evaluating the 48 mg and higher 64 mg dosages has the potential to provide a more complete assessment of the drug’s effects on weight loss, waist circumference, cardiometabolic health and liver-related outcomes.”

“In parallel, we continued to broaden the potential clinical utility of vanoglipel (DA-1241). During the quarter, we presented preclinical combination data at the ADA 2026 Scientific Sessions, demonstrating synergistic effects with both resmetirom in MASH and metformin in type 2 diabetes, while a peer-reviewed publication further highlighted the anti-fibrotic potential of GPR119 agonism. Together, these findings reinforce our strategy of advancing vanoglipel as a differentiated combination backbone for metabolic and liver diseases, designed to complement established and emerging therapies across cardiometabolic disorders.”

​

Second Quarter 2026 and Subsequent Highlights

​

​

Anticipated Clinical Milestones

​

​

Second Quarter Financial and Operating Results

​

​

R&D expenses were approximately $5.6 million for the six months ended June 30, 2026, as compared to approximately $4.6 million for the six months ended June 30, 2025. The approximately $0.9 million increase was primarily attributable to $1.2 million in higher direct R&D expenses related to DA-1726 product development, partially offset by (i) $0.2 million in lower direct R&D expenses related to vanoglipel product development and (ii) $0.1 million in lower indirect employee compensation and benefits costs.

​

​

G&A expenses were approximately $3.8 million for the six months ended June 30, 2026, as compared to approximately $3.5 million for the six months ended June 30, 2025. The approximately $0.3 million increase was primarily attributable to (i) $0.1 million in higher consulting expenditures, (ii) approximately $0.1 million in higher employee compensation and benefits costs, and (iii) $0.1 million in higher other G&A expenses, which was primarily related to higher franchise tax expenses.

​

​

Total operating expenses were approximately $9.4 million for the six months ended June 30, 2026, compared to approximately $8.2 million for the six months ended June 30, 2025. The approximately $1.2 million increase was primarily attributable to higher R&D and G&A expenses for the six months ended June 30, 2026.

​

​

Total other income was approximately $0.3 million for the six months ended June 30, 2026, as compared to approximately $0.5 million for the six months ended June 30, 2025. The approximately $0.2 million decrease was primarily attributable to (i) $0.1 million in lower gain from change in fair value of warrant liabilities due to the impact of the Company’s common stock’s decline in stock price and (ii) $0.1 million in lower interest income, net, due to lower balances of cash and cash equivalents and lower interest rates.

​

​

Net loss for the six months ended June 30, 2026, was approximately $9.1 million, or $1.69 per basic and diluted share, based on 5,398,683 weighted average shares of common stock, basic and diluted, compared with a net loss of approximately $7.7 million, or $6.59 per basic and diluted share, based on 1,162,692 weighted average shares of common stock, basic and diluted, for the six months ended June 30, 2025.

​

​

About MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting... (truncated)ass drug candidate targeting G-protein-coupled receptor 119 (GPR119). In preclinical studies, vanoglipel demonstrated a positive metabolic effect on glucose and lipid control, and also proved differentiated hepatic benefits reducing hepatic steatosis, hepatic inflammation, and liver fibrosis independent of metabolic improvement. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

​

For more information, please visit www.metaviatx.com.

​

Forward Looking Statements

Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", “potential”, "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia’s ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of preclinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

​

Contacts:

MetaVia

Marshall H. Woodworth

Chief Financial Officer

+1-857-299-1033 marshall.woodworth@metaviatx.com

​

Rx Communications Group

Michael Miller

+1-917-633-6086 mmiller@rxir.com

​

- Tables to Follow -

​

MetaVia Inc.

Condensed Consolidated Balance Sheets

(Unaudited - In thousands, except share and per share amounts)

​

​

​

​

MetaVia Inc.

Condensed Consolidated Statements of Operations

(Unaudited - In thousands, except share and per share amounts)

​

​

## Financial statements

### Income Statement (Three Months Ended June 30, — (Unaudited - In thousands, except share and per share amounts))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Operating expenses | Research and development | 3,478 | 2,320 | 5,579 | 4,647 |
| Operating expenses | General and administrative | 1,907 | 1,981 | 3,831 | 3,540 |
| Operating expenses | Total operating expenses | 5,385 | 4,301 | 9,410 | 8,187 |
| Operating expenses | Loss from operations | -5,385 | -4,301 | -9,410 | -8,187 |
| Other income (expense) | (Loss) gain from change in fair value of warrant liabilities | -4 | 160 | 113 | 247 |
| Other income (expense) | Interest income, net | 73 | 146 | 158 | 274 |
| Other income (expense) | Total other income | 69 | 306 | 271 | 521 |
| Other income (expense) | Loss before income taxes | -5,316 | -3,995 | -9,139 | -7,666 |
| Other income (expense) | Net loss | -5,316 | -3,995 | -9,139 | -7,666 |
| Other income (expense) | Loss per share of common stock, basic and diluted | -0.9 | -2.87 | -1.69 | -6.59 |
| Other income (expense) | Weighted average shares of common stock, basic and diluted | 5,931,875 | 1,389,753 | 5,398,683 | 1,162,692 |

### Balance Sheet ((Unaudited - In thousands, except share and per share amounts))

| | As of – June 30, 2026 | As of – December 31, 2025 |
|---|---:|---:|
| Current assets | Cash and cash equivalents | 12,634 | 10,278 |
| Current assets | Prepaid expenses and other current assets | 433 | 597 |
| Current assets | Total current assets | 13,067 | 10,875 |
| Current assets | Property and equipment, net | 8 | 17 |
| Current assets | Right-of-use asset | 175 | 210 |
| Current assets | Other assets | 21 | 21 |
| Current assets | Total assets | 13,271 | 11,123 |
| Current liabilities | Accounts payable | 921 | 1,060 |
| Current liabilities | Clinical trial accrued liabilities | 2,825 | 79 |
| Current liabilities | Accrued expenses and other current liabilities | 606 | 993 |
| Current liabilities | Warrant liabilities | 23 | 136 |
| Current liabilities | Related party payable | 1,897 | 3,312 |
| Current liabilities | Lease liability, short-term | 74 | 68 |
| Current liabilities | Total current liabilities | 6,346 | 5,648 |
| Current liabilities | Lease liability, long-term | 103 | 142 |
| Current liabilities | Total liabilities | 6,449 | 5,790 |
| Stockholders’ equity | Common stock, $0.001 par value per share, 100,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 6,575,656 and 2,308,294 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 7 | 2 |
| Stockholders’ equity | Additional paid–in capital | 164,784 | 154,161 |
| Stockholders’ equity | Accumulated deficit | -157,969 | -148,830 |
| Stockholders’ equity | Total stockholders’ equity | 6,822 | 5,333 |
| Stockholders’ equity | Total liabilities and stockholders’ equity | 13,271 | 11,123 |
